Results 181 to 190 of about 642,659 (199)

A rare case of alirocumab (PCSK9 inhibitor)-associated acute interstitial nephritis. [PDF]

Clin Nephrol Case Stud
Habib N, Yuan C, Lightle A, Monrroy M, Mehta S.   +4 more
europepmc   +1 more source

Relationship Between Timing of PCSK9 Inhibitor Monoclonal Antibody Initiation and Clinical Outcomes in Patients with Prior Cardiovascular Events. [PDF]

Ther Clin Risk Manag
Sidelnikov E, Kalich BA, Miglins ML, Multani JK, Tuly R, Hawkins K, Baber U.   +6 more
europepmc   +1 more source

Optimizing PCSK9 Inhibitor Integration for Cardiovascular Disease Management in Pakistan. [PDF]

Clin Med Insights Cardiol
Saleem MS, Samad S, Ahmed SS, Mehmood N.
europepmc   +1 more source

Exploring research trends and hotspots on PCSK9 inhibitor studies: a bibliometric and visual analysis spanning 2007 to 2023. [PDF]

Front Cardiovasc Med
Lai P, Xu S, Liu Z, Ling J, Tian K, Yan J, Chen D, Zhong Y, Xue J.   +8 more
europepmc   +1 more source

Author Correction: The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. [PDF]

NPJ Aging
Ikegami Y, Inoue I, Inoue K, Shinoda Y, Iida S, Goto S, Nakano T, Shimada A, Noda M.   +8 more
europepmc   +1 more source

Evolocumab induced short-term biliary stent blockage and acute cholangitis in a jaundice patient with pancreatic carcinoma: a rare complication of PCSK9 inhibitor. [PDF]

Hepatobiliary Surg Nutr
He K, Wang Y, Chen S, Wang J, Cheng S, Li J, Wang Z.   +6 more
europepmc   +1 more source

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. [PDF]

Eur Heart J Cardiovasc Pharmacother
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG, ODYSSEY OUTCOMES Investigators.   +16 more
europepmc   +1 more source

Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis. [PDF]

BMC Cardiovasc Disord
Zhang S, Sun L, Xu X, Zhang Y, Chen Q.
europepmc   +1 more source

Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings. [PDF]

Adv Ther
Muntner P, Ghazi L, Jones J, Dhalwani N, Poudel B, Wen Y, Chen L, Wang Z, Bittner V, Kalich B, Farkouh ME, Woodward M, Colantonio LD, Rosenson RS.   +13 more
europepmc   +1 more source